ALZHEIMER'S DISEASE

This study is testing different dosing schedules for the Alzheimer's drug donanemab to find the best balance between clearing harmful brain plaques and minimizing a serious side effect called ARIA-E, which is brain swelling. It involves about 1,175 adults with early memory proble…

This study is testing whether adding a new investigational drug called E2814 to an existing Alzheimer's medication (lecanemab) is safe and can better slow the disease. It will involve about 105 people with early-stage Alzheimer's disease. Researchers will measure changes in a spe…

This study is testing a daily oral medication, RO7269162, to see if it is safe and if it can reduce the buildup of certain proteins in the brains of people who are at risk for or in the very early stage of Alzheimer's disease. It will involve about 256 participants who either hav…

This study is testing two new personalized treatments for older adults with Alzheimer's disease or mild cognitive impairment. One part uses a gentle, non-invasive brain stimulation technique, while the other uses a computer-based training program tailored to each person's needs. …

This study is testing whether consuming olive pomace oil, a byproduct of olive oil production, can reduce harmful brain inflammation in people with early-stage Alzheimer's disease. Researchers are comparing the effects of this oil to a common sunflower oil by measuring blood mark…

This study is testing whether a new oral drug, XBD173, can improve how blood flows in the brain in response to mental activity in people with Alzheimer's disease. About 51 participants with mild to moderate Alzheimer's will take either the drug or a placebo (dummy pill) for 28 da…

This large Phase 3 study is testing whether the experimental drug remternetug can delay worsening of memory, thinking, and daily function in people with early Alzheimer's disease. About 1,400 participants will receive either remternetug or a placebo for up to 5 years to see which…

This study is testing whether an investigational intravenous drug called GSK4527226 can slow the progression of early Alzheimer's disease. It will involve 367 people with mild cognitive impairment or mild dementia due to Alzheimer's, who will receive either one of two doses of th…

This study is testing the drug lecanemab in people who have a genetic form of Alzheimer's disease and have already been in a related long-term trial. The main goal is to see if aggressively removing amyloid plaque from the brain years before symptoms typically appear can signific…

This study is testing whether a simple blood test can identify people at high risk for Alzheimer's disease brain changes, even before symptoms appear. It will enroll 2000 adults aged 50-80, some with and some without memory concerns. The goal is to create a community-based screen…

This study is testing whether a new website tool called WeCareToFeedDysphagia can help reduce stress and burden for caregivers of dementia patients who have trouble swallowing. Researchers will compare caregivers who use the website tool to those who don't, measuring their stress…

This study is testing whether learning specific memory techniques can help improve thinking skills in adults over 50 who are noticing early memory concerns. Researchers will compare 80 participants who either receive structured memory training or just general information. The goa…

This study is testing whether a special sensory-based occupational therapy can help people with moderate Alzheimer's disease. Over four weeks, participants will experience a controlled environment with lights, sounds, and textures designed to improve mood, reduce agitation, and s…

This study aims to find out if smartphones, wearables, and home sensors can detect very early signs of Alzheimer's disease by measuring changes in a person's daily activities. It will enroll 3,500 people, including healthy volunteers and those with different stages of memory prob…

This study examines donated brain tissue and lab-grown brain cells to understand how conditions like schizophrenia, depression, bipolar disorder, Alzheimer's, and frontotemporal dementia affect the connections between brain cells (synapses). Researchers will analyze genetic and p…